摘要
目的探讨乳腺癌组织中PFKFB3的表达及其与临床预后的关系。方法选取2012年1月至2012年8月间广东医科大学附属医院诊治的63例乳腺癌患者,采用免疫组化SP法检测癌组织和相应癌旁组织中PFKFB3蛋白表达,并分析其与各临床病理特征的相关性。结果63例乳腺癌患者机体中的PFKFB3蛋白阳性表达主要定位于乳腺癌细胞的胞核内,仅有少部分表达于胞浆中。乳腺癌细胞PFKFB3蛋白阳性表达率为61.9%(39/63),癌旁组织为23.8%(15/63),两者比较,差异有统计学意义(P<0.05)。乳腺癌患者的年龄、组织学类型和肿瘤部位与PFKFB3蛋白表达无明显相关性,差异无统计学意义(P>0.05);而肿瘤分级、肿瘤直径、分子分型及淋巴结转移与PFKFB3蛋白表达密切相关,差异均有统计学意义(均P<0.05)。乳腺癌患者均给予手术治疗。手术5年后,PFKFB3蛋白表达为阳性者的生存率为61.5%(24/39),中位生存时间为(5.30±0.52)年,阴性者的生存率为87.5%(21/24),中位生存时间为(9.74±0.96)年。PFKFB3蛋白表达阳性者的生存率和中位生存时间均低于阴性者,两者比较,差异有统计学意义(P<0.05)。单因素分析结果显示,患者PFKFB3蛋白表达、肿瘤分级、原发肿瘤直径、淋巴结转移和分子分型等与患者预后相关,差异均有统计学意义(P<0.05),患者年龄、肿瘤部位、组织学类型与预后无相关性,差异无统计学意义(P>0.05)。结论乳腺癌患者机体中PFKFB3蛋白呈高表达,对维持癌症进展具有重要作用,可为临床治疗乳腺癌和改善预后提供新线索与研究靶点。
Objective To study the expression and significance of PFKFB3 in breast cancer tissues.Methods A total of 63 patients with breast cancer were selected at Affiliated Hospital of Guangdong Medical University from January 2012 to August 2012.Immunohistochemistry with streptavidin peroxidase were utilized to detect the expression of PFKFB3 in breast cancer tissues and in the paracancerous tissues.The association between the expression of PFKFB3 and pathological parameters was analyzed.Results The positive expression of PFKFB3 was mainly located in nucleus of breast cancer cells and only minority of it was located in endochylema.The positive expression rate of PFKFB3 was 61.9%(39/63)in the breast cancer tissues which was higher than 23.8%(15/63)in the paracancerous tissues(P<0.05).Tumor grade,tumor size,molecular typing and lymph node metastasis were closely associated with the expression of PFKFB3.The survival rate and median survival time were lower in patients with positive expression of PFKFB3 than in patients with negative expression of PFKFB3,Univariate analysis showed that the expression of PFKFB3,tumor location and histological type were not associated with the prognosis(P>0.05).Conclusion The expression of PFKFB3 is high in patients with breast cancer,which plays a key role in promoting the progression of cancer.It provides new clues and research targets for the clinical treatment of breast cancer and improvement in the prognosis.
作者
景志亮
陈永华
周金钊
JING Zhi-liang;CHEN Yong-hua;ZHOU Jin-zhao(Department of Pathology,Affiliated Hospital of Guangdong Medical University,Zhanjiang 524000,China)
出处
《中国肿瘤临床与康复》
2021年第11期1312-1315,共4页
Chinese Journal of Clinical Oncology and Rehabilitation